A pharmacological mouse model suggests a novel risk pathway for postpartum psychosis by Humby, Trevor et al.
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Postpartum  psychosis  (PP)  is  a severe  psychiatric  disorder  affecting  a small  proportion  of  new  mothers
shortly  after  childbirth.  The molecular  pathophysiology  underlying  the  disorder  is currently  poorly  under-
stood,  and  there  are no  amenable  animal  models  for  the  condition;  maternal  deﬁciency  for  the  enzyme
steroid  sulfatase  has  been  proposed  as  a potential  risk  mechanism.  Here  we  show  that  inhibition  of
steroid  sulfatase  with  667-COUMATE  (10  mg/kg  p.o.)  in new  mouse  mothers  results  in  behavioural  abnor-
malities  that can  be partially  alleviated  by the  administration  of  the  clinically-efﬁcacious  antipsychotic
ziprasidone  (0.3–1.0  mg/kg  i.p.). The  pattern  of  behavioural  abnormalities  in 667-COUMATE-treated  mice
implicated  a genetic  substrate  at 21–23  cM  on chromosome  15;  of  the  17  genes  within  this  chromosomal
interval,  only  one  (Nov/Ccn3)  was  signiﬁcantly  differentially  expressed  in the  brains  of  vehicle  and  667-
COUMATE-treated  mice.  Two  additional  members  of  the  Ccn  family  (Ccn2/Ctgf  and Ccn4/Wisp1)  were  also
signiﬁcantly  differentially  expressed  between  the  two  groups,  as  were  three  further  genes  co-expressed
with  Nov/Ccn3  in brain (Arhgdig)  or  previously  implicated  in  disorder  risk  by  clinical  studies  (Adcy8  and
Ccl2).  The  expression  of  Nov/Ccn3,  but not  of  the  other  differentially-expressed  genes,  could be  normalised
by  ziprasidone  administration  (1.0 mg/kg).  NOV/CCN3  lies  directly  under  a linkage  peak  for PP  risk  at  8q24,
and the  associated  protein  possesses  numerous  characteristics  that  make  it an  excellent  candidate  medi-
ator of  PP  risk. Our  data  suggest  the  667-COUMATE-treated  mouse  as  a model  for PP  with  some  degree  of
face,  construct,  and  predictive  validity,  and  implicate  a novel,  and  biologically-plausible,  molecular  risk
pathway  for PP.
ublis©  2016  The  Authors.  P
. Introduction
Postpartum psychosis (PP) is a severe psychiatric disorder
ccurring shortly after childbirth in 1–2 out of every 1000 mothers
Sit et al., 2006). The disorder is characterised by hallucinations,
elusions, cognitive disorganisation and mood problems, and is
ssociated with an increased risk of maternal suicide or infanti-
ide (Sit et al., 2006). The pathophysiological basis of PP is poorly
nderstood due, in part, to the lack of an amenable animal model.
∗ Corresponding author at: Cardiff University School of Psychology, 70, Park Place,
ardiff CF10 3AT, UK.
E-mail addresses: humbyt@cardiff.ac.uk (T. Humby), CrossES@cardiff.ac.uk
E.S. Cross), laurenmesser94@gmail.com (L. Messer), silvia 2i2@hotmail.com
S. Guerrero), daviesw4@cardiff.ac.uk (W.  Davies).
ttp://dx.doi.org/10.1016/j.psyneuen.2016.09.019
306-4530/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
The identiﬁcation of biomarkers associated with increased risk is a
key goal for ensuring early clinical intervention.
Increased PP risk is associated with a personal or family history
of psychotic disorder (notably bipolar disorder), with precipitous
drops in circulating oestrogens following childbirth, with obstet-
ric complications including pre-eclampsia, and with psychosocial
stressors (Sit et al., 2006). Small genetic linkage and association
studies have implicated regions of chromosome 16p13 and 8q24
(Jones et al., 2007) and serotonergic abnormalities (Kumar et al.,
2007) respectively, but have not identiﬁed robust candidate genes.
Recently, immune system (Bergink et al., 2013) and tryptophan-
kynurenine pathway (Veen et al., 2016) disruptions have been
demonstrated in PP, whilst regular smoking is associated with
reduced risk (Di Florio et al., 2015).
Maternal deﬁciency for the enzyme steroid sulfatase (STS) may
predispose to PP (Davies, 2012); STS converts sulfated steroids
to their non-sulfated forms (e.g. dehydroepiandrosterone sulfate,
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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HEAS, to DHEA) which may  act as precursors for oestrogens and
ndrogens (Davies, 2012). Maternal STS deﬁciency is associated
ith obstetric complications (Fernandes et al., 2010), whilst in
ealthy individuals, DHEAS serum levels positively correlate with
ostpartum psychoticism (Marrs et al., 2009); decreased postpar-
um DHEA levels are associated with activation of the maternal
mmune system (Tagawa et al., 2004).
In the ﬁrst part of the study (Experiment 1), we tested whether
cute inhibition of steroid sulfatase in new mouse mothers would
licit behavioural and gene expression changes of relevance to PP.
TS was inhibited using 667-COUMATE (also known as STX64), a
rug that systemically and irreversibly inhibits enzyme activity
y >90% in rodents at the dose used here (Purohit et al., 2000).
TS inhibition was indexed indirectly by measuring serum levels
f DHEA(S), and levels of the stress hormone corticosterone were
lso measured. The behavioural tasks assayed aspects of emotional
eactivity, activity and sensorimotor gating that are commonly per-
urbed in psychotic disorders; pup maltreatment or infanticide,
hich may  represent a surrogate measure of PP in animals (Quilter
t al., 2007) was also recorded. In Experiment 2, we  tested whether
67-COUMATE-induced behavioural and gene expression changes
ould be reversed by administration of clinically-relevant doses of
he atypical antipsychotic drug ziprasidone (Sit et al., 2006).
. Materials and methods
.1. Subjects and husbandry
Virgin C57BL/6JOlaHsd female mice (aged 12–26 weeks, origi-
ally obtained from Envigo UK and bred within Cardiff University
chool of Psychology), were housed in trios with males of the same
train. 3–5 days before giving birth, females were housed individu-
lly and were monitored closely until birth. Mice were maintained
n ad libitum food and water, in a temperature, humidity and
ight-controlled room (21 ± 2 ◦C, 50 ± 10% humidity, lights on at
700hr for 12 h) and were regularly inspected for signs of ill health.
xperiments were performed according to the UK Animal Scientiﬁc
rocedures Act (1986).
.2. Drug administration
.2.1. Experiment 1
<12 h after giving birth, mothers were injected per os (p.o.)
ith either vehicle solution (tetrahydrofuran:polyethylene gly-
ol 400: distilled water in a 1:6:3 ratio (Ireson et al., 2004)),
 = 14) or 667-COUMATE (10 mg/kg, Sigma-Aldrich, UK) in the same
ehicle (n = 17) in a pseudo-randomised manner. Mothers were
dministered the same treatment 48 h after this ﬁrst injection. The
67-COUMATE administration regime was based upon previously-
ublished pharmacokinetic data in rodents (Ireson et al., 2004;
urohit et al., 2000) and was intended to provide maximal enzyme
nhibition across the postpartum period whilst minimising off-
arget effects. Injections were performed between 09:00–10:00 h.
ehavioural testing was carried out 24 h after the second injection
etween 09:00–13:00 h.
.2.2. Experiment 2
<12 h after giving birth, mothers were injected per os (p.o.)
ith 667-COUMATE (10 mg/kg) as above. 24 h after the ﬁrst injec-
ion, mice were injected intraperitoneally (i.p.) with either vehicle
olution (1% methylcellulose in 0.9% saline) or one of two doses
f ziprasidone hydrochloride (0.3 mg/kg or 1.0 mg/kg (free-base
oncentrations) Sigma-Aldrich, UK) in the same vehicle in a pseudo-
andomised manner. 24 h later, mice received a second injection of
67-COUMATE (10 mg/kg), and 23 h after this, mice received a ﬁnal
njection of vehicle, 0.3 mg/kg, or 1.0 mg/kg ziprasidone. Injectionsrinology 74 (2016) 363–370
were performed between 08:30–10:00h. The three experimental
groups were: mice which received 667-COUMATE (10 mg/kg) with
ziprasidone (0 mg/kg)(CVCV group, n = 16), mice which received
667-COUMATE (10 mg/kg) with ziprasidone (0.3 mg/kg)(CZCZ0.3
group, n = 16), and mice which received 667-COUMATE (10 mg/kg)
with ziprasidone (1.0 mg/kg)(CZCZ1.0 group, n = 8). Ziprasidone
doses were selected to have minimal effects on activity (Kalinichev
and Dawson, 2011). Behavioural testing was  carried out 1hr after
the ﬁnal injection between the hours of 09:30–13:00 h.
2.3. Homecage monitoring and behavioural analysis
Prior to injections, mother/pup health, litter sizes and weights,
and maternal weights were recorded; pup deaths or signs of mater-
nal aggression towards the pups were noted. These measures
allowed us to assess whether the drug regimes were adversely
affecting gross maternal and/or pup health, and/or pup maltreat-
ment or infanticide; we  were particularly concerned that inhibition
of STS in the mother’s mammary gland may  affect provisioning of
her pups. Only mothers who gave birth to at least one live pup were
included in the study.
Mothers were initially behaviourally tested on an elevated plus-
maze (Isles et al., 2004) to assay anxiety-related and exploratory
phenotypes. Mice were placed in a closed arm, and allowed to
explore the apparatus freely for 5mins. Their lateral and verti-
cal (‘rearing’) activity was  objectively tracked using Ethovision
Observer software Version 3.0.15 (Noldus Information Technology,
The Netherlands); additional measures of vertical and lateral explo-
ration (head dips from the open arms and stretch attend postures)
and emotional reactivity (defecation) were recorded manually. Key
measures of interest were the ratio of open arm:closed arm time
and latency to ﬁrst entry of the open arms (indexing anxiety),
entries into the closed arms (an index of within-maze activity min-
imally confounded by anxiety), numbers of rears/head dips and
stretch-attend postures, and numbers of fecal boli. Two seconds
per animal were added to the open arm latency measure obtained
from Ethovision to account for the time lag between putting the
animal on the maze and initiating tracking. Following testing on
the elevated plus-maze, basal activity level was tested in the dark
using locomotor cages (Isles et al., 2004). The number of infra-
red beam breaks made over a 1hr session (4 × 15 min  bins) was
recorded. Finally, sensorimotor gating was assayed using a startle
and prepulse inhibition (PPI) paradigm (Dent et al., 2014); the main
measures of interest were startle response over ﬁrst three pulse
alone trials (an index of emotional reactivity), the startle response
for four levels of prepulse at 0, 4, 8 and 16 dB above background
(P120, PP4P120, PP8P120 and PP16P120 respectively, an index of
habituated startle and PPI), and startle response over pulse-alone
trials with varying stimulus intensity (an index of auditory acu-
ity). The behavioural tests were administered in order of increasing
severity such that performance on the latter tests would not be sub-
stantially inﬂuenced by prior exposure to potential stressors. Mice
were returned to their homecage for 5–10min between behavioural
tests.
2.4. Culling and tissue collection
3 h after behavioural testing, subjects were culled by cervical
dislocation. Trunk blood was  collected in BD SST Microtainer Gold
tubes (BD Biosciences) and serum extracted according to the manu-
facturer’s instructions prior to storage at −80 ◦C. Whole brains were
removed, bisected sagitally, and frozen on dry ice.
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Table  1
A comparison of physiological, behavioural and endocrine markers across vehicle and 667-COUMATE-treated mothers.
Measure of interest Vehicle 667-COUMATE Statistical signiﬁcance
Litter measures
Initial litter size 6.9 ± 0.4 pups 6.6 ± 0.6 pups t[29] = 0.48, p = 0.63
Number of pups found dead per mother across course of experiment 1.5 (95%CI: 1–2) 1.0 (95%CI: 0–2) p = 0.60
Elevated plus maze measures
100x (open arm time/closed + open arm time) 25 ± 4 31 ± 4 t[29] = −1.11, p = 0.28
Latency to ﬁrst open arm entry (s) 9.7 (95%CI: 3.8–14.3) 2.4 (95%CI: 2.1–4.5) p = 0.021
Closed arm entries 24 ± 2 21 ± 2 t[29] = 1.04, p = 0.31
Rears  0 (95%CI: 0–0) 21 (95%CI: 0–81) p = 0.040
Head  dips 46 ± 9 35 ± 5 t[20.4] = 1.09, p = 0.29
Stretch-attend postures 18.5 (95%CI: 9–61) 14 (95%CI: 8–29) p = 0.42
Fecal  boli 0 (95%CI: 0–2) 1 (95%CI: 0–2.5) p = 0.38
Maternal serum steroid hormone measurements
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.5. Steroid hormone analysis
Serum steroid hormone levels were assayed by ELISA (dehy-
roepiandrosterone sulfate (DHEAS) and DHEA DRG International;
orticosterone, Enzo Biosciences) according to the manufacturer’s
nstructions, with sample dilution as necessary and samples run
n triplicate. Samples were taken from vehicle-treated mice (n = 9
or DHEA and corticosterone, and n = 10 for DHEAS), and 667-
OUMATE treated mice (n = 15 for all compounds); DHEAS and
HEA levels were both measured in vehicle-treated (n = 8) and
67-COUMATE-treated (n = 15) mice. Standard curves were deter-
ined using SigmaPlot 11.0 (Systat Software Inc.) according to the
quation: y = y0 + (ab/(b + x)) where y0, a and b are constants.
.6. RNA extraction, cDNA synthesis and quantitative PCR
nalysis
High-quality total RNA was extracted from the right hemi-
phere of the brain using RNeasy Universal Midi Kit (Qiagen)
ccording to the manufacturer’s instructions. For Experiment 1,
NA was extracted from vehicle-treated mice and 667-COUMATE
reated mice (n = 12 per group). For Experiment 2, RNA was
xtracted from mice administered 667-COUMATE with ziprasidone
0 mg/kg)(n = 11), mice administered 667-COUMATE with ziprasi-
one (0.3 mg/kg)(n = 11) and mice administered 667-COUMATE
ith ziprasidone (1.0 mg/kg)(n = 6). 20 l cDNA solution was syn-
hesised from 4 to 5 g RNA using RNA-to-cDNA EcoDry Premix
ith random primers (Clontech), and was diluted 50-fold with dis-
illed water. Quantitative PCR analysis was performed using the
Ct method using Gapdh,  Hprt and Rn18 s as housekeeping genes
Trent et al., 2014) (primer sequences available in Supplemental
able S1 in the online version at DOI: 10.1016/j.psyneuen.2016.09.
19).
.7. Statistics
Data were analysed using SPSS 20 (IBM Corporation, New York).
ormal data (as determined by Shapiro-Wilk test) were ana-
ysed by unpaired two-tailed (unless stated otherwise) t-test/One
ay  ANOVA or Two Way  Repeated Measures or Mixed Model
NOVA, with a between-group factor of DRUG TREATMENT and a
ithin-group factor of TIMEPOINT or PULSE TYPE. Startle data were
nalysed using bodyweight and ‘pressure exerted in the absence of stimulus’ as covariates. Where sphericity assumptions were vio-
ated in ANOVA, Greenhouse-Geisser corrected degrees of freedom
alues are presented. Post hoc pairwise comparisons were per-
ormed using the Sidak test. Non-parametric data were analysed 0.0–45.5) 32.2 (95%CI: 10.7–43.1) p = 0.07 (one-tailed)
CI: 0.000-0.232) 0.052 (95%CI: 0.000–0.119) p = 0.45 (one-tailed)
 5.5–13.8) 10.0 (95%CI: 3.2–19.1) p = 0.91
by one or two-tailed Mann—Whitney U test. Correlational analyses
for normally and non-normally distributed data were performed
using Pearson test or Spearman Rank-Order Correlation respec-
tively. P-values of <0.05 were regarded as nominally signiﬁcant.
Normally-distributed data are reported as mean values ± standard
error of the mean, and non-parametric data as median values with
95% conﬁdence intervals (obtained by bootstrapping).
3. Results
3.1. Experiment 1
3.1.1. Litter sizes, maternal behaviours and maternal and pup
health
Initial litter sizes (i.e. prior to the ﬁrst injection) were compara-
ble between the vehicle and 667-COUMATE treatment groups; the
number of pups found dead was  equivalently low for both groups
(Table 1). All mothers built and maintained normal nests.
667-COUMATE treatment in the mother did not affect gross
health or bodyweight (DRUG TREATMENT: F[1,29] = 1.18, p = 0.29,
DRUG TREATMENT x TIMEPOINT: F[3,87] = 2.15, p = 0.10). Pup
health was normal across the course of the experiment; mean pup
weight increased equivalently across both experimental groups
from ∼1.30 g to ∼1.75 g (DRUG TREATMENT: F[1,29] = 0.42, p = 0.52,
TIMEPOINT: F[2.1, 61.1] = 3.39, p = 0.038, DRUG TREATMENT x
TIMEPOINT: F[2.1, 61.1] = 0.47, p = 0.64).
3.1.2. Elevated plus-maze
Treatment with 667-COUMATE in new mothers resulted in a
signiﬁcantly reduced latency to enter the open arms of the maze,
and a signiﬁcantly greater propensity towards rearing; these effects
occurred in the absence of signiﬁcant effects on other behavioural
measures assessed in this test (Table 1).
3.1.3. Locomotor activity
The experimental groups showed an equivalent decrease in
activity over the course of the 1hr test session (from ∼515 to
∼305 infrared beam breaks per 15 min  bin) (DRUG TREATMENT:
F[1,29] = 0.00, p = 0.97; TIMEPOINT: F[1.68,48.7] = 24.6, p < 0.001;
DRUG TREATMENT x TIMEPOINT: F[1.68,48.7] = 0.40, p = 0.64).
3.1.4. Startle and prepulse inhibition (PPI)
There was no signiﬁcant effect of treatment on initial mean
startle response to three pulses of 120 dB (i.e. 55 dB above back-
ground)(vehicle: 55 ± 10 arbitrary startle units, 667-COUMATE:
61 ± 15 arbitrary startle units, F[1,27] = 0.01, p = 0.94).
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f  a small prepulse stimulus 4 dB above background (PP4P120)(A). There were no s
tartle  response (B), nor with startle response with varying levels of pulse intensity
On the ‘pulse alone’ and ‘prepulse’ trials, there was  the expected
attern of reduced startle response with increasing levels of pre-
ulse (PULSE TYPE, F[3,29] = 54.4, p < 0.001); whilst there was no
ain effect of DRUG TREATMENT (F[1,29.5] = 1.41, p = 0.25), there
as a signiﬁcant DRUG TREATMENT x PULSE TYPE interaction
F[3,29] = 3.05, p = 0.044) with 667-COUMATE-treated mice dis-
laying reduced startle when no, or a minimal, prepulse stimulus
as present (Fig. 1A). Although there was the expected trend of
ncreased startle inhibition with increasing volumes of the prepulse
F[1.66,48.1] = 86.5, p < 0.001), there was no signiﬁcant main effect
f DRUG TREATMENT (F[1,29] = 0.39, p = 0.85) nor any signiﬁcant
RUG TREATMENT x PULSE TYPE interaction (F[1.66,48.1] = 0.70,
 = 0.48) (Fig. 1B).
Increasing stimulus volume from background (70 dB) to 120 dB
as associated with increased startle response in both groups
onsistent with normal hearing and motor reactivity (DRUG
REATMENT (F[1,29.2] = 1.70, p = 0.20, PULSE TYPE F[5,29] = 17.39,
 < 0.001, DRUG TREATMENT x PULSE TYPE (F[5,29] = 1.68,
 = 0.17)(Fig. 1C); on average, startle in drug-treated mice at pulses
f 110 dB and 120 dB was lower than in vehicle-treated mice, con-
istent with the data presented above.
.1.5. Steroid hormone levels
Serum DHEAS levels showed the expected trend towards higher
evels in the drug-treated group, whilst serum DHEA levels were,
n average, lower in the drug-treated group (Table 1). For mice
n which both DHEAS and DHEA levels were measured, the ratio
f median DHEAS:median DHEA levels was 189 for the vehicle-
reated group and 620 for the 667-COUMATE treated group (i.e.
3.3fold higher in drug-treated mice than in vehicle-treated mice).
onsistent with our previous data in adult male MF1 mice (Trent
ig. 2. Nov/Ccn3 was the only gene within the candidate gene interval (21–23 cM,  chr 15) th
wo  further Ccn family genes (B) and three positional/functional candidate genes (C) were sicle-treated mice in the absence of no prepulse stimulus (P120) or in the presence
cant differences between the two groups with regard to prepulse inhibition of the
20 dB)(C).
et al., 2013), there was  a signiﬁcant inverse correlation between
serum DHEA levels and 1hr locomotor activity in postpartum
females (rs = −0.416, p = 0.043). Serum corticosterone levels did not
differ between groups (Table 1).
3.1.6. Gene expression
Our behavioural data indicated drug-induced effects on elevated
plus-maze rearing and latency to enter the open arms in the same
task; intriguingly, these two measures are strongly inﬂuenced by
a small quantitative trait locus between 21–23 cM on mouse chro-
mosome 15 (Henderson et al., 2004), a region syntenic with human
chromosome 8q24. Thus, we compared the expression of 17 genes
with known products within this interval (http://www.informatics.
jax.org/marker, last accessed 2nd September 2016) in vehicle and
667-COUMATE-treated hemibrains. Only one between-group com-
parison (for Nov, also known as Ccn3) was  signiﬁcant, with higher
expression in drug-treated tissue (t[22] = −2.19, p = 0.039, Fig. 2A)
(p ≥ 0.12 for other comparisons).
The nominally-signiﬁcant effect of 667-COUMATE treatment
on Nov/Ccn3 expression would not survive correction for multiple
testing. We  considered that if signiﬁcant effects of 667-COUMATE
treatment on the expression of one or more of the other ﬁve
members of the Nov/Ccn gene family were to be found, this
would provide additional conﬁdence that the original ﬁnding was
a true effect. Both the expression of Ctgf/Ccn2 and Wisp1/Ccn4
were signiﬁcantly increased in 667-COUMATE-treated tissue
(t[22] = −2.15, p = 0.043 and t[17.27] = −2.47, p = 0.024 respec-
tively), whilst expression levels of Cyr61/Ccn1,  Wisp2/Ccn5 and
Wisp3/Ccn6 did not differ between the two  conditions (t[22] = 0.01,
p = 0.99, p = 0.11, and t[22] = 0.67, p = 0.51 respectively)(Fig. 2B).
at was differentially expressed in vehicle and 667-COUMATE treated hemibrain (A);
igniﬁcantly differentially expressed between the two experimental groups.*p < 0.05.
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Table  2
A comparison of physiological and behavioural markers across new mouse mothers treated with 667-COUMATE and vehicle (CVCV), with 667-COUMATE and 0.3 mg/kg
ziprasidone (CZCZ0.3) or with 667-COUMATE and 1.0 mg/kg ziprasidone (CZCZ1.0). *signiﬁcantly different from other two  groups (p < 0.05).
Measure of interest CVCV CZCZ0.3 CZCZ1.0 Statistical signiﬁcance
Litter measures
Initial litter size 7.0 (95%CI: 6.0–8.0) 6.0 (95%CI: 5.0–7.0) 6.5 (95% CI: 6.0–8.0) p = 0.26
Number of pups found
dead per mother across
course of experiment
0 (95%CI: 0–0) 0 (95%CI: 0–2) 0 (95%CI: 0–1) p = 0.54
Elevated plus maze measures
Rearing 0.5 (95%CI: 0–12.5) 2.5 (95%CI: 0–14) 0 (0–0) p = 0.20
Latency to ﬁrst open arm entry (s) 7.8 (95%CI: 4.5–15.4) 8.7 (95%CI: 5.0-12.8) 11.1 (95%CI: 6.0-26.4) p = 0.51
Closed arm entries 28 ± 3* 20 ± 2 12 ± 3 F[2,37] = 9.44, p < 0.001
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Total infra-red beam breaks in 1hr 1837 ± 182, 15
We  then assessed the expression of three immune-related genes
Ccl2, Cxcl1 and Il33) whose activity is thought to be regulated
y Nov/Ccn3 (Le Dreau et al., 2010; Perbal, 2006), and that have
reviously been implicated in PP (Ccl2) or bipolar disorder (Il33)
athogenesis (Barbosa et al., 2014; Bergink et al., 2013). Brain Ccl2
xpression levels were signiﬁcantly elevated in 667-COUMATE-
reated mice (t[22] = −2.28, p = 0.033), whilst Cxcl1 and Il33 levels
ere equivalent between the two groups (t[22] = −0.10, p = 0.92
nd t[22] = 0.30, p = 0.77 respectively)(Fig. 2C). We  also examined
he expression of: a) murine orthologues of three genes sug-
ested as positional candidates for PP (Jones et al., 2007) (Abat
nd Grin2a at 16p13, and Adcy8 at 8q24), b) two genes within
6p13 whose expression correlates with CTGF/CCN2 or NOV/CCN3
xpression in developing human brain tissue (Li et al., 2016) (Hba-
1/a2 and Arhgdig), and c) two genes suggested by genomewide
ssociation studies as candidates for bipolar disorder (Cacna1c and
dz4/Tenm4)(Harrison, 2016). Adcy8 expression was  signiﬁcantly
igher in the brains of 667-COUMATE-treated mice (t[22] = −2.17,
 = 0.041), consistent with previous evidence that adenylate cyclase
Adcy) activity might be involved in the mechanoregulation
f the Ccn genes (Schild and Trueb, 2004); Arhgdig expres-
ion was also increased in 667-COUMATE-treated brain relative
o vehicle-treated brain (t[22] = −2.375, p = 0.027)(Fig. 2C), and
ov/Ccn3 and Arhgdig expression (as indexed by Ct values)
as signiﬁcantly positively correlated across both experimental
roups (r = 0.51, p = 0.01). There was no effect of DRUG TREAT-
ENT on the expression of Abat, Grin2a,  Hba-a1/a2,  Cacna1c
r Odz4/Tenm4 (t[22] = −0.29, p = 0.78, t[22] = −0.67, p = 0.51,
[20.2] = −1.04, p = 0.31, t[22] = −1.13, p = 0.27 and t[22] = −1.09,
 = 0.29 respectively) (Fig. 2C).
Finally, we examined the expression of two serotonergic sys-
em genes: Htr2a (encoding a primary target for antipsychotic drug
ction) and Htr2c (the expression of which may  be affected by
ts deﬁciency, Trent et al., 2012). The expression level of neither
f these two genes was affected by DRUG TREATMENT (Htr2a:
[22] = 0.08, p = 0.94, and Htr2c: t[22] = 0.27, p = 0.79)(Fig. 2C). Over-
ll, our gene expression data indicate a high degree of speciﬁcity to
he effects of 667-COUMATE.
.2. Experiment 2
.2.1. Litter sizes, maternal behaviours and maternal and pup
ealth
Initial live litter sizes (i.e. prior to any injections) did not differ
etween the CVCV, CZCZ0.3 and CZCZ1.0 groups; the number of
ups found dead was equivalently low for all groups (Table 2). All
others built and maintained normal nests.
Maternal health and bodyweight was not signiﬁcantly differ-
ntially affected by DRUG TREATMENT (F[2,37] = 1.83, p = 0.18,
RUG TREATMENT x TIMEPOINT: F[1.4, 76.0] = 0.34, p = 0.83). Pup72 1294 ± 233 F[2,37] = 1.75, p = 0.19
health also appeared normal across the course of the experiment;
mean pup weight increased equivalently across all groups (from
∼1.30 g to ∼1.80 g) (DRUG TREATMENT: F[2,37] = 0.47, p = 0.63,
TIMEPOINT: F[1.5, 57.0] = 2.02, p = 0.15, DRUG TREATMENT x TIME-
POINT: F[3.1, 57.0] = 0.40, p = 0.76).
3.2.2. Behaviour
We  hypothesised that, in 667-COUMATE-treated mice, ziprasi-
done administration would attenuate rearing in the elevated
plus-maze and increase latency to enter the open arms in the
absence of minimal effects on activity. Overall, rearing levels were
low and equivalent across the three groups (Table 2). Whilst median
ﬁrst open arm entry latencies did increase across the three groups,
this was  not signiﬁcant (Table 2). The interpretation of the rearing
and open arm entry data is complicated by the fact that both doses
of ziprasidone tended to reduce activity in the aversive elevated
plus-maze, as indexed by closed arm entries (Table 2). In contrast
to the closed arm entry data in the elevated plus-maze, we found
no signiﬁcant difference between groups in terms of their overall
number of beam breaks in the relatively non-aversive locomotor
activity paradigm (Table 2), indicating that the reduced activity
in the antipsychotic-treated groups in the elevated plus-maze test
may  have been partially due to the anxiogenic effect of ziprasidone
in 667-COUMATE treated mice.
We  further hypothesised that, in 667-COUMATE-treated mice,
the administration of ziprasidone would enhance the startle
response, particularly when a prepulse stimulus was  absent or
small. Ziprasidone did dose-dependently enhance startle, though
for all values of pulse-prepulse pairings (DRUG TREATMENT:
F[2148] = 9.44, p < 0.001, PULSE TYPE: F[3148] = 3.29, p = 0.023,
DRUG TREATMENT x PULSE TYPE: F[6148] = 0.08, p = 1.00, Fig. 3A).
3.2.3. Gene expression
We compared the brain expression of genes whose expres-
sion differed signiﬁcantly in Experiment 1 (i.e. Nov/Ccn3, Ctgf/Ccn2,
Wisp1/Ccn4, Ccl2, Adcy8,  and Arhgdig in mice treated with 667-
COUMATE plus one of three doses of ziprasidone (0, 0.3 or
1.0 mg/kg)(Fig. 3B). Nov/Ccn3 expression was signiﬁcantly affected
by DRUG TREATMENT, with signiﬁcantly lower expression in the
CZCZ1.0 group relative to the other two groups (F[2,25] = 5.07,
p = 0.014, p < 0.05 for pairwise comparisons with 1.0 mg/kg group).
Adcy8 expression was signiﬁcantly affected by DRUG TREATMENT,
with higher expression in the CZCZ1.0 group relative to the other
two groups (p < 0.01, p < 0.005 for pairwise comparisons with CVCV
and CZCZ0.3 groups respectively). The expression of Ctgf/Ccn2,
Wisp1/Ccn4, Ccl2 and Arhgdig genes did not differ as a function of
DRUG TREATMENT (F[2,25] = 0.90, p = 0.42, F[2,25] = 0.54, p = 0.59,
F[2,25] = 3.36, p = 0.051, and p = 0.44 respectively).
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eig. 3. Treatment with ziprasidone dose-dependently enhanced the low startle re
igniﬁcantly reduced Nov/Ccn3 gene expression and increased Adcy8 expression in 
. Discussion
The molecular pathophysiology of PP is poorly deﬁned, partially
s a consequence of having no amenable animal models; the main
nimal model for PP currently is the ‘porcine infanticide model’
Quilter et al., 2007) which, although valuable, is impractical for
arge-scale experimental studies and does not accurately reﬂect the
P phenotype (most mothers with PP are not infanticidal).
We used pharmacological techniques to produce an
xperimentally-amenable mouse model of PP with some degree of
ace, construct and predictive validity that may  indicate underlying
athogenic processes. Brieﬂy, acute postpartum inhibition of the
teroid sulfatase enzyme in mouse mothers, predicted on the
asis of theory to give rise to PP-related phenotypes (‘construct
alidity’)(Davies, 2012), elicits phenotypes of relevance to PP. In
erms of behavioural face validity, 667-COUMATE-treated mice
xhibited: a) a reduced startle response with preserved PPI (a
henotype seen in bipolar disorder and dependent upon levels
f pro-inﬂammatory cytokines (Beck and Catuzzi, 2013)) and b)
lterations in elevated plus-maze behaviour, likely to be inﬂu-
nced by a region of chromosome 15 (syntenic to the PP candidate
egion 8q24 in man). These behavioural phenotypes were not con-
ounded by the effects of 667-COUMATE on maternal/pup health,
r maternal activity. In terms of endocrinological face validity,
67-COUMATE treated mice, like women with PP (Epperson and
allew, 2006), exhibited normal corticosterone/cortisol levels. In
erms of molecular face validity, our model showed alterations
n the brain expression of a gene previously implicated in bipolar
isorder and PP (Adcy8)  (Jones et al., 2007) and a gene encoding
 pro-inﬂammatory cytokine (Ccl2) whose levels are elevated in
erum of individuals with PP (Bergink et al., 2013); the abnormal
xpression of these genes may  contribute towards the behavioural
roﬁles of the drug-treated mice. As one 667-COUMATE-induced
ehavioural phenotype (reduced startle response) could be
eversed by the administration of an antipsychotic used to treat
P, the model may  also have some degree of predictive validity.
he extent to which the model recapitulates other features of PP
emains to be established. Moreover, whilst 667-COUMATE is an
ffective inhibitor of STS, it may  have off-target effects, notably one induced by 667-COUMATE administration (A). The highest dose of ziprasidone
OUMATE-treated mice (B). *p < 0.05.
carbonic anhydrase II (Ho et al., 2003); these off-target effects have
no gross effects on maternal health, but their contribution to the
more subtle changes in drug-treated mice is difﬁcult to quantify.
In support of steroid sulfatase inhibition-mediated effects on
the gene expression differences reported here, DHEA inﬂuences
Ctgf/Ccn2 (Zhang et al., 2013) and Ccl2 (or MCP-1)(Wang et al.,
2011) expression and secretion in females.
Our gene expression work indicated altered expression of sev-
eral members of the Ccn gene family in 667-COUMATE treated
brain. This gene family, which encodes a number of secreted extra-
cellular matrix-associated proteins expressed in the brain (Malik
et al., 2015), represents an interesting candidate for effects on
PP risk given: a) its known involvement in female reproductive
function (Winterhager and Gellhaus, 2014), b) its dynamic brain
expression throughout pregnancy and the puerperium (Ray et al.,
2015), c) its modulation of Notch and Wnt  signalling pathways
(Winterhager and Gellhaus, 2014) that are disrupted in bipolar
disorder (Pedroso et al., 2012) and cases of postpartum psychi-
atric disturbance (Pantoni et al., 2005) and d) the known role of
extracellular-matrix dysfunction in the pathophysiology of mood
disorders (Lubbers et al., 2014). Additionally, Ccn gene expression
may  be altered by the administration of psychotomimetic agents
(Sakuma et al., 2015), by social stress (Stankiewicz et al., 2015), and
by small molecules including cytokines and serotonin (Chen et al.,
2014).
Using methods agnostic to gene function, we have speciﬁcally
implicated NOV/CCN3, encoding a biologically-relevant protein: a)
its overexpression is associated with abnormal maternal behaviour
which can be reversed through antipsychotic administration
(present study), b) it is located ∼138 cM on human chromosome
8, below the linkage peak indicated from a sample of individuals
with bipolar affective puerperal psychosis (137.5–147.5 cM)  (Jones
et al., 2007), c) the associated protein is thought to modulate intra-
cellular calcium signalling (Lombet et al., 2003) a process that goes
awry in both bipolar disorder (Harrison, 2016) and PP (Riley and
Watt, 1985), d) its expression is repressed by oestrogen (Vendrell
et al., 2004), e) it encodes a regulator of placental angiogenesis and
its expression is perturbed in cases of pre-eclampsia (Winterhager
and Gellhaus, 2014), f) it is highly expressed in the cortex and
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imbic system of the adult human brain (Malik et al., 2015), g)
t can regulate axonal outgrowth of callosal projection neurons
Park et al., 2015) consistent with corpus callosum abnormalities
n PP cases (Udaya et al., 2015), h) it lies adjacent to a polymor-
hism associated with smoking cessation (Argos et al., 2014) and its
xpression is downregulated in female tissues exposed to cigarette
moke (Gueugnon et al., 2016), and i) small genomic duplications
ncompassing NOV/CCN3 have been associated with bipolar disor-
er (Macayran et al., 2006). Given possible thyroid dysfunction in
P (Bergink et al., 2011), it is also interesting that cortical Nov/Ccn3
nd Adcy8 expression is regulated by 3,5,3′-triiodo-l-thyronine (T3)
Berbel et al., 2014). Finally, recent work has shown that wildtype
ouse mothers carrying pups with genetic mutations perturbing
lacental function exhibit abnormal behaviour and signiﬁcantly
ncreased hippocampal Nov/Ccn3 gene expression (Creeth et al.,
015 and Hugo Creeth, pers. comm.).
The study has two main limitations. First, in the absence of data
n behaviour or gene expression in non-postpartum mice adminis-
ered 667-COUMATE, we cannot ascertain whether STS deﬁciency
nd its sequelae confer risk of abnormal maternal phenotypes in
he postpartum period only, or confer risk of abnormal maternal
ehaviour though mechanisms operating both within, and outside,
he postpartum period. Second, for the gene expression analyses we
sed a hemibrain dissection given that no individual brain region
as robustly been shown to function abnormally in PP cases, and to
apture large gene expression changes within one brain region or
maller gene changes throughout multiple brain regions; however,
his approach may  be insensitive to small gene expression changes
n speciﬁc brain regions.
. Conclusions
Our results indicate that acute postpartum steroid sulfatase deﬁ-
iency results in abnormal maternal behaviour (at least in mice),
nd begin to deﬁne a brain pathway that may  feasibly be disturbed
n women diagnosed with PP i.e. signalling from the extracellular
atrix to the cytoplasm via Ccn proteins, transmembrane proteins
uch as integrins and Notch, and intracellular molecules. Further
etails of the molecular pathway(s) by which steroid sulfatase
nhibition inﬂuences postpartum behaviour may  be revealed by
ypothesis-free gene expression analyses in our mouse model. Our
ata offer support for STS (Xp22.3), NOV/CCN3, WISP1/CCN4 and
DCY8 (8q24) and ARHGDIG (16p13) as functional and positional
andidate genes for PP risk, and indicate that analyses comparing
enetic variation within these genes, or their physiological corre-
ates (e.g. serum DHEA(S) levels), in samples of healthy nulliparous
nd parous controls and PP cases is warranted.
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